WT1 126-134 peptide

Overview

WT1 126-134 peptide is a Wilms' tumor oncogene protein ( WT1 ) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity ( K d = 0.2 nM) with the humanized monoclonal antibody ( IgG1 ). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies.

Application

Products | Products > Peptides | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > MHC

Product Information

• Catalog No.: HY-P11084
• CAS No.: 256952-63-3
• Molecular Formula: C52H77N13O12S
• Molecular Weight: 1108.31
• Purity: 99.98%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source